The tweet was deleted by the author.
But we saved everything 🙂.
REGENXBIO participated in the international gathering of the MPS community in Florence, engaging with International MPS Network members and attending the International Symposium on MPS and Related Lysosomal Diseases.
The company emphasized the importance of global collaboration as it works alongside partners and researchers in the field. REGENXBIO highlighted the critical need for cooperative efforts in driving forward research and potential therapies for MPS and related lysosomal diseases. Details from the symposium underscore a shared focus on innovation, patient advocacy, and accelerating scientific developments.
REGENXBIO has presented promising pivotal data for its RGX-202 Duchenne muscular dystrophy program at a national conference, according to a previous report. The company also participated in the ASGCTherapy Annual Meeting, engaging with peers to discuss advances in gene therapy research, as detailed in an earlier update. These events highlight REGENXBIO's continued focus on innovation and scientific collaboration in rare disease research.